Epigenomics dysregulation and therapeutics in neurodegeneration

Anne‐Laurence Boutillier · 2025

Read Epigenomics dysregulation and therapeutics in neurodegeneration by Anne‐Laurence Boutillier (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709599.txt.

Description

Anne-Laurence Boutillier reviews in 2025 how changes in gene control may drive brain decline with age, and how drugs might target those changes. Aging is the main risk factor for diseases like Alzheimer's. Along with age, the set of chemical marks that switch genes on and off also shifts, but which shifts are shared across diseases is not clear.

The review draws on mouse work that compared young and old brains, and brains with a disease linked protein build up. Studies read gene marks across the whole genome and paired them with measures of which genes were active. Some tests worked at the level of single cell types. The author sums up which marks change, where they agree across models, and which drug ideas follow. The goal is targets that could slow brain decline.

Catalog record

CREATORAnne‐Laurence Boutillier
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11709599

Browse the full library · About the Tower of Babel